Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
March 15, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
Conference Call & Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical...
Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15
March 13, 2018 09:18 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., March 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire to Present at Two Investor Conferences
March 08, 2018 08:00 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., March 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled
February 27, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
February 21, 2018 06:00 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Pricing of $22 Million Public Offering of Common Stock
February 08, 2018 09:00 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Proposed Public Offering of Common Stock
February 07, 2018 16:32 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
January 31, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands...
Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients
January 17, 2018 06:30 ET
|
Gemphire Therapeutics Inc.
On Track to Report Top-Line Data from Phase 2b Trial in Second Quarter of 2018 LIVONIA, Mich., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage...
Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program
December 21, 2017 06:00 ET
|
Gemphire Therapeutics Inc.
Phase 2a trial will investigate gemcabene in Familial Partial Lipodystrophy (FPL) – a rare genetic disease with characteristic presentation of cardiovascular disease and NASH Gemcabene has a...